arrow
A

Andreas Schneeweiß

german cancer research center (dkfz)
H指数:98
被引数:5.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive Liquid Biopsy Testing in Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Patients: First Results from Routine Clinical Practice

转移性激素受体阳性HER2阴性乳腺癌患者中的全面液体活检检测:来自常规临床实践的首批结果

2026-05-010
PRE
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial
2026-04-290
OAAI
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study

tiragolumab、atezolizumab联合化疗在早期或PD-L1阳性晚期三阴性乳腺癌中的安全性与有效性:一项 Ib 期研究

2025-11-250
OAAI
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

远处无病生存期作为早期乳腺癌新辅助治疗随机试验中总生存期的替代终点:GBG和AGO-B研究组试验的合并分析

2025-11-240
PRE
Use of Bevacizumab for Patients with FIGO Stage IIIB to IV Epithelial Ovarian Cancer undergoing Primary Debulking Surgery and its Association with Oncologic Outcomes: A Cancer Registry Study

贝伐珠单抗用于接受初次肿瘤细胞减灭术的FIGO分期IIIB至IV期上皮性卵巢癌患者的应用及其与肿瘤学结局的关联:一项癌症登记研究

2025-11-060
OAAI
Characterizing novel patient-derived breast cancer brain metastases models through high-throughput drug screening and integrative omics profiling

通过高通量药物筛选和整合组学分析表征新型的患者来源性乳腺癌脑转移模型

2025-11-010
OAAI
Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

在转移性乳腺癌中实施精准肿瘤学:全面基因组分析的临床影响——CATCH研究经验

2025-10-310
OAAI
P11.37.B NOVEL PATIENT-DERIVED BREAST CANCER BRAIN METASTASES MODELS CHARACTERIZED BY LARGE-SCALE DRUG SCREENING AND INTEGRATIVE MULTI-OMICS PROFILING

P11.37.B 基于患者来源的乳腺癌脑转移瘤新型模型,通过大规模药物筛选和整合多组学分析进行表征

2025-10-030
OA
Overall Survival in Metastatic Breast Cancer Patients: Real-World Data from 1,000 Patients Treated at the NCT Heidelberg between 2014 and 2022

转移性乳腺癌患者总生存期:来自NCT海德堡2014年至2022年间治疗的1,000例患者的真实世界数据

2025-10-010
PRE
AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025

AGO乳腺癌委员会关于乳腺癌手术治疗的建议:妇科肿瘤工作组(AGO)2025年更新

2025-09-170
PREAI
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

在接受一线CDK4/6抑制剂治疗后,转移性激素受体阳性、HER2阴性乳腺癌患者选择化疗方案的预后影响

2025-08-050
OA
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk

绝经前早期激素受体阳性、HER2阴性且复发风险增加的乳腺癌患者中,芳香化酶抑制剂、他莫昔芬和卵巢功能抑制的实际情况应用。

BREAST
IF7.9
2025-06-010
OAAI
Effects of aerobic or resistance exercise during neoadjuvant chemotherapy on tumor response and therapy completion in women with breast cancer: The randomized controlled BENEFIT trial

有氧或抗阻运动在辅助新辅助化疗期间对乳腺癌患者肿瘤反应和治疗方案完成度的影响:随机对照BENEFIT试验

2025-05-280
OAAI
Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy The POLAR Randomized Clinical Trial

手部冷却和加压在预防紫杉烷类诱导神经病变中的疗效:POLAR随机临床试验

2025-04-010
PRE
Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism

来自无肿瘤的转移前器官的微小细胞外囊泡和颗粒(sEVPs)促进乳腺癌转移并支持器官特异性转移

2025-03-081
OA
Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility
2025-02-010
OAAI